• Thumbnail for Liraglutide
    Liraglutide, sold under the brand names Victoza and Saxenda among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity...
    33 KB (2,855 words) - 21:09, 12 September 2024
  • Danish scientist and university professor. She led the development of liraglutide and oversaw the development of semaglutide, two notable drugs approved...
    17 KB (1,882 words) - 23:34, 27 September 2024
  • Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes...
    7 KB (479 words) - 11:42, 6 August 2024
  • Thumbnail for Semaglutide
    at Novo Nordisk led by the scientist Lotte Bjerre Knudsen developed liraglutide, a glucagon-like peptide-1 receptor agonist that could be used to treat...
    66 KB (5,428 words) - 08:55, 26 September 2024
  • dose compared to liraglutide in some of the measured parameters after ten weeks of daily intraperitoneal injections with liraglutide (2.5 or 25 nmol/kg)...
    21 KB (1,930 words) - 06:59, 1 July 2024
  • blood. With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are...
    50 KB (5,222 words) - 18:06, 23 August 2024
  • Thumbnail for Glucagon-like peptide-1
    diabetes GLP-1 receptor agonists : albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, tirzepatide and semaglutide, the latter of which is marketed...
    26 KB (3,386 words) - 20:05, 10 September 2024
  • been studied, showing improvements in biochemistry and colonic transit. Liraglutide, a GLP-1 receptor agonist had unexpected effects in clinical cases with...
    24 KB (2,732 words) - 02:16, 21 September 2024
  • Thumbnail for Anti-obesity medication
    GLP-1 receptor agonists became popular for weight loss. The medications liraglutide, naltrexone/bupropion, orlistat, semaglutide, and tirzepatide are approved...
    53 KB (4,991 words) - 18:16, 16 September 2024
  • Thumbnail for Dulaglutide
    S2CID 73313508. "Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes" (Press release)...
    16 KB (1,542 words) - 20:53, 21 September 2024